Table 1 Patients’ characteristics
Characteristics | Total RET-fusion (n = 232) | Immunophenotyped cohort (n = 194) | Treatment cohort (n = 38) | P-value |
|---|---|---|---|---|
Median age (range), years | 59(30–88) | 59(30–88) | 57 (39–71) | 0.62 |
Sex | 0.87 | |||
Male | 100 (43.1) | 85 (43.8) | 15 (39.5) | |
Female | 132 (56.9) | 109 (56.2) | 23 (60.5) | |
Smoking history | 0.84 | |||
No | 188 (81.0) | 156 (80.4) | 32 (84.2) | |
Yes | 44 (19.0) | 38 (19.6) | 6 (15.8) | |
Histology | 0.08 | |||
Adenocarcinoma | 224 (96.6) | 189 (97.4) | 35 (92.1) | |
Squamous | 2 (0.9) | 1 (0.5) | 1 (2.6) | |
Neuroendocrine carcinoma | 3 (1,3) | 1 (0.5) | 2 (5.3) | |
Atypical carcinoid | 2 (0.9) | 2 (1.0) | 0 (0) | |
Others | 1 (0.4) | 1 (0.5) | 0 (0) | |
Stage | 0.000 | |||
I | 84 (36.2) | 84 (43.3) | 0 (0) | |
II | 0 (0) | 0 (0) | 0 (0) | |
III | 34 (14.7) | 31 (16.0) | 3 (7.9) | |
IV | 114 (49.1) | 79 (40.7) | 35 (92.1) | |
Brain metastases | 0.000 | |||
Yes | 21 (9.1) | 8 (4.1) | 13 (34.2) | |
No | 211 (90.9) | 186 (95.9) | 25 (65.8) | |
ICI combination therapy | ||||
First line | 17 (44.7) | |||
Second or later line | 21 (55.3) | |||